Abstract
In this study, we show that comprehensive DNA profiling using whole genome sequencing (WGS) can offer novel insights into ovarian carcinoma (OC). First, using WGS of 185 OC with HRDetect profiling, a mutational signature-based algorithm for homologous recombination repair deficiency (HRD), we found that patients with HRDetect-high OC had significantly better overall survival, with a median of 6.2 years compared to 4.1 years for those with lower score OC. Second, the rest of the OCs are not simply non-HRD - some carry distinguishing rearrangement signatures that are strongly prognostic. Third, in an independent cohort of 77 patients, we demonstrate predictive value; HRDetect-high patients exhibited better responses to PARP inhibitors (PARPi) (median progression-free survival of 11.1 months versus 7.1 months; overall response rate of 54% versus 22.5%). Critical next steps include fine-tuning therapeutic vulnerabilities associated with the diverse rearrangement signatures, and harnessing the full potential of WGS for OC clinical trial stratification.
Competing Interest Statement
K.B has received honoraria from Immunogen, AstraZeneca, and American Society of Clinical Oncology. E.M.S is on the scientific advisory board for Ideaya Biosciences and receives consulting fees and stock options. H.R.D., A.D. and S.N.-Z. hold patents or have submitted applications on clinical algorithms of mutational signatures [HRDetect (PCT/EP2017/060294), clinical use of signatures (PCT/EP2017/060289), rearrangement signature methods (PCT/EP2017/060279), clinical predictor (PCT/EP2017/060298), MMRDetect (PCT/EP2022/057387), and hotspots for chromosomal rearrangements (PCT/EP2017/060298].
Funding Statement
We gratefully acknowledge the support for K.B research from the American Society of Clinical Oncology/Conquer Cancer Foundation's Career Development Grant and the generosity of Roger Wilcox. The research in E.S. laboratory received funding from the Department of Defense Ovarian Cancer Research Program Clinical Development Award (OC160274). Additionally, this research was supported by Seattle Translational Tumor Research (STTR). The work in S.N.-Z. laboratory was made possible through funding from several prestigious sources: Cancer Research UK (CRUK) Advanced Clinician Scientist Award (C60100/A23916), the Dr. Josef Steiner Cancer Research Award 2019, the Basser Gray Prime Award 2020, the CRUK Grand Challenge Award (C60100/A25274), and the National Institute of Health Research (NIHR) Research Professorship (NIHR301627). Support was also provided by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Washington gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos